MDcide

AI-BASED DECISIONS

LISTENING TO THE DATA,
PROTECTING PATIENT HEALTH

MDcide delivers large-scale, real-time patients screening that improves diagnosis time, reduces health complications and as a result it saves high costs to patients, caregivers and health insurers.

Disease Early Detection

We are saving lives and improving patients’ health trajectory by predicting risk and enabling early detection of health conditions at their asymptomatic phase

Machine Learning

Our algorithms were trained on millions of electronic health records and will continue to adapt to a dynamically changing health care landscape

Treatments and Diagnostics

Our recommendation system uses unique patient profile and trained ML models to suggest your physicians the best course of treatment and additional exams

Who we are

Passionate pharma & IT leaders on AI revolution mission

We bring our extensive and diverse backgrounds in the fields of data science, pharmacology, IT and engineering and sprinkle a healthy dose of passion for bringing about real change in quality of life preservation.

What we do

Saving lives with AI powered early detection

Our machine learning models and cutting edge algorithms have been trained on millions of electronic health records with one purpose in mind: listen to what the data has to say about the patient’s risk for silent diseases and to alert the physician in the early stages. Early detection can be a critical factor in the positive outcome and disease management, and our models are invaluable tools in the physician’s toolbox.

MDcide reduces stroke risks and heart failures caused by Atrial Fibrillation (AFib)

AFib is a major risk factor for blood clots, stroke and heart failures. AFib is often asymptotic in its early stages, but is manageable if identified at an early stage. MDcide AFib Predictor offers real breakthrough in early diagnosis. It alerts primary care physicians when their patients are found to be in high risk and can recommend tests and treatments predicted to be effective for the patient based on his unique profile. Healthcare providers that implement MDcide AFib Predictor improve quality of life for millions and save high treatment costs.

Our process

HMOs and Health insurers' worldwide partner with MDcide to deliver innovative screening and preventive care

1

Apply MDcide AI Products using electronic health records, containing lab results (like CBC), historic diagnosis and demographic data, while protecting patients' privacy.

2

The algorithms that have been trained on millions of health records, has learned to predict health conditions like AFib. It runs in the background and processes an output that is embedded into the physician's system. The physician doesn't need to order any special tests for this purpose!

3

Physicians will get an alert for their patients in high risk, delivering scores and recommendations for next immediate steps: monitoring, tests, medications and follow-up procedures.

4

Patients in high risk are identified 6-18 months prior to diagnosis that is based on reported symptoms. The health trajectory of millions of patients is redirected and catastrophic complications, such as stroke and heart attacks are being averted.

ABOUT US

Committed to accelerate data assets into value based healthcare system

We believe that developing advanced innovative solutions, based on data, will transform primary healthcare and bring great savings. We bring years of experience in leadership, creativity, data solutions implementation and innovative technologies adaption.
Our team is inspired with can-do attitude, strive to excellence culture and the will to make an impact in the digital-health arena.

CO-FOUNDERS

Gil Tomer, PhD, MBA

CTO

An executive and tech-entrepreneur with more than 20 years' experience in pharma industry.

Talia Friedman, Eng., MBA

CEO

An information systems engineer, VP product and senior technology consultant.

Our impact

Timely and accurate diagnoses and treatment

MDcide demonstrates how healthcare providers and their patients can gain from the data they own, with the ability to accurately predict Atrial Fibrillation in patients more than 6 months earlier than it is diagnosed by primary care professionals. The outcome is improved personalized care, faster decision making, better disease management and costs savings to patients, care-givers, HMOs and healthcare insurers.

Our partners

Interested in finding out more?
Get in touch